Kidney Cancer Diagnostics Market: By Type of Condition, By Type of Test, Uninalysis, Blood Chemistry Studies), By End user and Geography
Kidney Cancer Diagnostics Market size was valued at US$ 3.2 billion in 2023, growing at a CAGR of 6.1% from 2024-2030. Kidney cancer begins when healthy cells in kidneys change and grow abnormally forming a mass called renal cortical tumor. A tumor can be malignant, indolent or benign. There are three main types of kidney cancers amongst renal cell cancer is the most common type of cancer in adults and wilms tumors are common in children. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing.
Study Period
2024-2030Base Year
2023CAGR
6.1%Largest Market
North AmericaFastest Growing Market
Europe
Increase in the prevalence and incidence of kidney cancer and growing geriatric population propels the growth of the Kidney Cancer Diagnostics market globally. Furthermore increase in awareness regarding kidney cancers, drastic lifestyle changes, government initiatives drives the growth of Kidney Cancer Diagnostics market globally. Moreover technological advancements, advanced healthcare services and increase in healthcare expenditure also propels the market growth of endometrial cancer diagnostics globally. However, rise in number of patient expirations, stringent regulatory framework, high cost associated with the tests and treatments, adverse effects and lack of awareness about innovative technologies may hinder the growth of the market globally.
North America kidney cancer diagnostics market and Europe Kidney Cancer Diagnostics market is growing due to increase in the prevalence of kidney cancer cases, increase in ageing population, presence of favorable reimbursement policies, high healthcare expenditure, well established healthcare infrastructure. Asia Pacific market also growing at a significant rate, which is attributed to increase health awareness regarding kidney cancer, growing economy of emerging countries. . Latin America market and Middle East and Africa market are haing lucrative growth oppurtunities owing to the geographical expansion by market players in those regions and increase in the expenditure of healthcare.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 3.2 billion |
|
Market CAGR |
6.1% |
|
By Type of Condition |
|
|
By Type of Test |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The Kidney Cancer Diagnostics Market size was valued at US$ 3.2 billion in 2023, growing at a CAGR of 6.1% from 2024-2030.
The Kidney Cancer Diagnostics Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Europe is the fastest-growing for Kidney Cancer Diagnostics Market
| 1.Executive Summary |
| 2.Global Kidney Cancer Diagnostics Market Introduction |
| 2.1.Global Kidney Cancer Diagnostics Market - Taxonomy |
| 2.2.Global Kidney Cancer Diagnostics Market - Definitions |
| 2.2.1.Type of Condition |
| 2.2.2.Type of Test |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Kidney Cancer Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Kidney Cancer Diagnostics Market Analysis, 2019-2023 and Forecast 2024-2030 |
| 4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Kidney Cancer Diagnostics Market By Type of Condition, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 5.1. Renal Cell Carcinoma |
| 5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Urothelial Carcinoma |
| 5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sarcoma |
| 5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Wilms Tumor |
| 5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Lymphoma |
| 5.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Kidney Cancer Diagnostics Market By Type of Test, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 6.1. Ultrasound |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. CT Scan |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. MRI |
| 6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Radioisotope Scan |
| 6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Tissue Biopsy |
| 6.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Intravenous Pyelogram (IVP) |
| 6.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Uninalysis |
| 6.7.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Blood Chemistry Studies |
| 6.8.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 7.Global Kidney Cancer Diagnostics Market By End User, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 7.1. Diagnostic Centers |
| 7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospitals |
| 7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ambulatory Surgical Centers |
| 7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Kidney Cancer Diagnostics Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Kidney Cancer Diagnostics Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 9.1. Type of Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Renal Cell Carcinoma |
| 9.1.2.Urothelial Carcinoma |
| 9.1.3.Sarcoma |
| 9.1.4.Wilms Tumor |
| 9.1.5.Lymphoma |
| 9.2. Type of Test Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Ultrasound |
| 9.2.2.CT Scan |
| 9.2.3.MRI |
| 9.2.4.Radioisotope Scan |
| 9.2.5.Tissue Biopsy |
| 9.2.6.Intravenous Pyelogram (IVP) |
| 9.2.7.Uninalysis |
| 9.2.8.Blood Chemistry Studies |
| 9.3. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Diagnostic Centers |
| 9.3.2.Hospitals |
| 9.3.3.Ambulatory Surgical Centers |
| 9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Kidney Cancer Diagnostics Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 10.1. Type of Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Renal Cell Carcinoma |
| 10.1.2.Urothelial Carcinoma |
| 10.1.3.Sarcoma |
| 10.1.4.Wilms Tumor |
| 10.1.5.Lymphoma |
| 10.2. Type of Test Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Ultrasound |
| 10.2.2.CT Scan |
| 10.2.3.MRI |
| 10.2.4.Radioisotope Scan |
| 10.2.5.Tissue Biopsy |
| 10.2.6.Intravenous Pyelogram (IVP) |
| 10.2.7.Uninalysis |
| 10.2.8.Blood Chemistry Studies |
| 10.3. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Diagnostic Centers |
| 10.3.2.Hospitals |
| 10.3.3.Ambulatory Surgical Centers |
| 10.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Kidney Cancer Diagnostics Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 11.1. Type of Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Renal Cell Carcinoma |
| 11.1.2.Urothelial Carcinoma |
| 11.1.3.Sarcoma |
| 11.1.4.Wilms Tumor |
| 11.1.5.Lymphoma |
| 11.2. Type of Test Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Ultrasound |
| 11.2.2.CT Scan |
| 11.2.3.MRI |
| 11.2.4.Radioisotope Scan |
| 11.2.5.Tissue Biopsy |
| 11.2.6.Intravenous Pyelogram (IVP) |
| 11.2.7.Uninalysis |
| 11.2.8.Blood Chemistry Studies |
| 11.3. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Diagnostic Centers |
| 11.3.2.Hospitals |
| 11.3.3.Ambulatory Surgical Centers |
| 11.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Kidney Cancer Diagnostics Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 12.1. Type of Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Renal Cell Carcinoma |
| 12.1.2.Urothelial Carcinoma |
| 12.1.3.Sarcoma |
| 12.1.4.Wilms Tumor |
| 12.1.5.Lymphoma |
| 12.2. Type of Test Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Ultrasound |
| 12.2.2.CT Scan |
| 12.2.3.MRI |
| 12.2.4.Radioisotope Scan |
| 12.2.5.Tissue Biopsy |
| 12.2.6.Intravenous Pyelogram (IVP) |
| 12.2.7.Uninalysis |
| 12.2.8.Blood Chemistry Studies |
| 12.3. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Diagnostic Centers |
| 12.3.2.Hospitals |
| 12.3.3.Ambulatory Surgical Centers |
| 12.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Kidney Cancer Diagnostics Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 13.1. Type of Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Renal Cell Carcinoma |
| 13.1.2.Urothelial Carcinoma |
| 13.1.3.Sarcoma |
| 13.1.4.Wilms Tumor |
| 13.1.5.Lymphoma |
| 13.2. Type of Test Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Ultrasound |
| 13.2.2.CT Scan |
| 13.2.3.MRI |
| 13.2.4.Radioisotope Scan |
| 13.2.5.Tissue Biopsy |
| 13.2.6.Intravenous Pyelogram (IVP) |
| 13.2.7.Uninalysis |
| 13.2.8.Blood Chemistry Studies |
| 13.3. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Diagnostic Centers |
| 13.3.2.Hospitals |
| 13.3.3.Ambulatory Surgical Centers |
| 13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Ariad Pharmaceuticals, Inc. (U.S) |
| 14.2.2.Merck & Co., Inc. (U.S) |
| 14.2.3.Abbott Laboratories (U.S) |
| 14.2.4.Siemens Healthcare Inc. (Germany) |
| 14.2.5.Hoffman-La Roche Ltd. (Switzerland) |
| 14.2.6.Becton, Dickinson & Co. (U.S) |
| 14.2.7.GlaxoSmithKline Plc., etc. (UK) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
